Matrix Capital, an employee-owned hedge fund, led a $190m funding round in Maze Therapeutics, a developer of a biotechnology platform. Additional investors include General Catalyst, a16z, Woodline Partners, Casdin Capital, City Hill Ventures, Foresite Capital, Driehaus Capital Management, Moore Strategic Ventures, Terra Magnum Capital Partners and NS Investments. “Over the past year, Maze has generated data across multiple disease areas and modalities. I am confident that Maze has emerged at precisely the right moment with the right people to execute on an ambitious and important mission, and I am proud of our team for the progress made in our pipeline to date. As we transition to a clinical-stage company, we believe this financing provides important resources to advance our pipeline and to uncover new genetic associations to develop precision medicines for patients with genetically defined diseases," Jason Coloma, Maze President and CEO.